ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
March 10 2022 - 7:00AM
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a
biotechnology company focused on the discovery and development of
therapeutics targeting
misfolded proteins such as
toxic oligomers implicated in the development of neurodegenerative
diseases, announced today that it will be presenting at the
upcoming AD/PDTM International Conference, to be held in Barcelona
Spain, March 15-20, 2022.
ProMIS Chief Development Officer, Dr. Johanne Kaplan, will
deliver an on-site oral presentation “Optimizing vaccine design for
Alzheimer’s disease: selective targeting of
computationally-derived conformational B cell epitopes of soluble
amyloid-beta toxic oligomers" as part of the AD/PDTM symposium
entitled: “Abeta and other targeting therapies in AD”. The
symposium is to be held on Sunday, March 20, 9:05-11:05 AM, local
time, in room 113 at the International Barcelona Convention
Center.
The presentation discusses the optimal design of an amyloid-beta
(Abeta) vaccine to elicit antibodies that are selective for
toxic Abeta oligomers
(ABO) without inducing a potentially detrimental immune response to
normal forms of Abeta.
Dr. Kaplan’s presentation will be available on the ProMIS
website (www.promisneurosciences.com) at the conclusion of the
AD/PDTM Conference on March 20th.
AD/PDTM is the groundbreaking series of Alzheimer’s and
Parkinson’s Diseases Conferences attracting international medical
and scientific professionals worldwide. The Conference is at the
forefront of unraveling the mechanisms and improving the treatment
of Alzheimer’s, Parkinson’s, and other related neurodegenerative
diseases. AD/PD™ Conferences uniquely combine distinct
neurodegenerative diseases in one setting and examine their
similarities and differences; there is a strong focus on mechanisms
of disease, prevention, and therapy.
About ProMIS
NeurosciencesProMIS Neurosciences, Inc. is a
development stage biotechnology company focused on discovering and
developing therapeutics selectively targeting toxic misfolded
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer’s disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
The Company’s proprietary target discovery engine is based on the
use of two complementary computational modeling techniques. The
Company applies its molecular dynamics, computational discovery
platform -ProMIS™ and Collective Coordinates - to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. ProMIS is headquartered in Toronto, Ontario,
with offices in Cambridge, Massachusetts. ProMIS is listed on the
Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF
To learn more, visit us at www.promisneurosciences.com, follow
us on Twitter and LinkedIn
For Investor Relations please contact:Alpine Equity
AdvisorsNicholas Rigopulos, Presidentnick@alpineequityadv.comTel.
617 901-0785
The TSX has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release. This information release
contains certain forward-looking information. Such information
involves known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and
therefore these statements should not be read as guarantees of
future performance or results. All forward-looking statements are
based on the Company's current beliefs as well as assumptions made
by and information currently available to it as well as other
factors. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks
and uncertainties identified by the Company in its public
securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
###
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jul 2023 to Jul 2024